share_log

截至2024 年6 月30 日止六個月的中期業績公告及委任獨立非執行董事

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Hong Kong Stock Exchange ·  Aug 15 17:33
Summary by Futu AI
京東健康於2024年6月30日公布了截至同年6月30日止六個月的中期業績，以及宣布委任廖家傑教授為獨立非執行董事。該中期業績顯示，公司收入達人民幣283億元，同比增長4.6%；毛利達人民幣67億元，同比增長8.0%；經營盈利達人民幣10.35億元，同比增長17.7%；除稅前盈利達人民幣24.39億元，同比增長33.2%；期間盈利達人民幣20.34億元，同比增長30.2%；期間非國際財務報告準則盈利達人民幣26.44億元，同比增長8.5%。公司在互聯網醫療服務方面持續創新，並強化醫藥健康產品供應鏈能力。此外，公司積極應對國家政策，推動數字化醫療服務發展。廖家傑教授的委任將自2024年8月15日起生效，其在醫療領域的豐富經驗將為公司帶來新的視角。
京東健康於2024年6月30日公布了截至同年6月30日止六個月的中期業績，以及宣布委任廖家傑教授為獨立非執行董事。該中期業績顯示，公司收入達人民幣283億元，同比增長4.6%；毛利達人民幣67億元，同比增長8.0%；經營盈利達人民幣10.35億元，同比增長17.7%；除稅前盈利達人民幣24.39億元，同比增長33.2%；期間盈利達人民幣20.34億元，同比增長30.2%；期間非國際財務報告準則盈利達人民幣26.44億元，同比增長8.5%。公司在互聯網醫療服務方面持續創新，並強化醫藥健康產品供應鏈能力。此外，公司積極應對國家政策，推動數字化醫療服務發展。廖家傑教授的委任將自2024年8月15日起生效，其在醫療領域的豐富經驗將為公司帶來新的視角。
JD Health announced its mid-year performance as of June 30, 2024, and appointed Professor Liao Jiajie as an independent non-executive director. The mid-year performance showed that the company's revenue reached 28.3 billion yuan, a year-on-year growth of 4.6%; gross profit reached 6.7 billion yuan, a year-on-year growth of 8.0%; operating profit reached 1.035 billion yuan, a year-on-year growth of 17.7%; pre-tax profit reached 2.439 billion yuan, a year-on-year growth of 33.2%; profit for the period reached 2.034 billion yuan, a year-on-year growth of 30.2%; and non-IFRS profit for the period reached 2.644 billion yuan, a year-on-year growth of 8.5%. The company continues to innovate in digital health services and strengthen its supply chain capabilities for medicine and health products. In addition, the company actively responds to national policies and promotes the development of digital healthcare services. Professor Liao Jiajie's appointment will take effect from August 15, 2024, and his extensive experience in the medical field will bring a new perspective to the company.
JD Health announced its mid-year performance as of June 30, 2024, and appointed Professor Liao Jiajie as an independent non-executive director. The mid-year performance showed that the company's revenue reached 28.3 billion yuan, a year-on-year growth of 4.6%; gross profit reached 6.7 billion yuan, a year-on-year growth of 8.0%; operating profit reached 1.035 billion yuan, a year-on-year growth of 17.7%; pre-tax profit reached 2.439 billion yuan, a year-on-year growth of 33.2%; profit for the period reached 2.034 billion yuan, a year-on-year growth of 30.2%; and non-IFRS profit for the period reached 2.644 billion yuan, a year-on-year growth of 8.5%. The company continues to innovate in digital health services and strengthen its supply chain capabilities for medicine and health products. In addition, the company actively responds to national policies and promotes the development of digital healthcare services. Professor Liao Jiajie's appointment will take effect from August 15, 2024, and his extensive experience in the medical field will bring a new perspective to the company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.